Tanezumab: A Detailed Dive into the 880266-57-9 Antibody Product
Tanezumab: A Detailed Dive into the 880266-57-9 Antibody Product
Blog Article
Tanezumab, identified by the catalog designation 880266-57-9, represents a therapeutic antibody reagent demonstrating significant promise in treating debilitating osteoarthritis pain. This modified antibody selectively targets nerve growth element , blocking its function and thereby lessening pain within affected joints . The ongoing data surrounding 880266-57-9 highlights its power to offer significant pain relief while potentially limiting the requirement for conventional analgesics. Further investigation are actively underway to completely evaluate its long-term well-being and efficacy .
Grasping Tanezumab's Function in Ache Control: An Antibody Perspective
Tanezumab, a unique treatment approach, offers a specific pathway in persistent pain management. As a humanized antibody, it precisely targets and prevents nerve expansion factor (NGF), a critical molecule engaged in sensory ache signaling. Unlike conventional opioid medications, tanezumab’s protein mechanism allows for a greater specific action, possibly reducing the risk of some common side effects associated with broad pain reduction. However, its immunological nature necessitates a detailed assessment of potential immune effects and extended consequences when employed within a complete pain therapy strategy.
Tanezumab Compound (880266-57-9): Composition, Grade & Functions
The Tanezumab Compound with the identifier 880266-57-9 is a essential component in various research applications, particularly concerning chronic inflammation treatment development. Achieving a high standard of quality is paramount; therefore, rigorous analysis protocols are employed to guarantee its appropriateness for intended use. Our manufacturing process focuses on maximizing purity , employing sophisticated purification techniques to remove contaminants . Typical characteristics include get more info a >95% purity grade as determined by HPLC and comprehensive examination for molecular integrity. The main applications revolve around its role as a scientific resource for investigating processes of arthritis progression and next-generation therapeutic interventions .
- Research Investigations
- Medical Development
- Pathway Studies
A Science Of Tanezumab: Analyzing the 880266-57-9 Antibody
Tanezumab, identified with the unique identifier 880266-57-9, represents a innovative therapeutic antibody targeting nerve development factor receptor (NGF). Its mechanism of effect revolves around specifically connecting to NGF, consequently reducing its role and later communication transduction. Scientists have shown that this biologic agent provides opportunity for alleviating chronic suffering, particularly in conditions like joint degeneration and peripheral back discomfort. Further investigations are continuing to completely characterize its impact and well-being data.
Recent Progress in The Study: Examining the The Substance
Current analyses surrounding tanezumab, a promising therapeutic agent, are increasingly directed on defining the role of the particular reagent, 880266-57-9. This identification and detailed assessment of this biological entity seems crucial for optimizing tanezumab's efficacy and lessening possible negative reactions. Preliminary findings indicate that it plays a important part in tanezumab's mechanism of action. More studies will be required to completely clarify the reagent’s impact.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}
Report this page